BEMRIST BREEZHALER 125/62.5 indacaterol (as acetate)/mometasone furoate 125/62.5 microgram powder for inhalation in hard capsule with inhaler Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bemrist breezhaler 125/62.5 indacaterol (as acetate)/mometasone furoate 125/62.5 microgram powder for inhalation in hard capsule with inhaler

grand medical pty ltd - mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - bemrist breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists

ATECTURA BREEZHALER 125/62.5 indacaterol (as acetate)/mometasone furoate 125/62.5 microgram powder for inhalation in hard capsule with inhaler Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

atectura breezhaler 125/62.5 indacaterol (as acetate)/mometasone furoate 125/62.5 microgram powder for inhalation in hard capsule with inhaler

novartis pharmaceuticals australia pty ltd - mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists

BEMRIST BREEZHALER 125/127.5 indacaterol (as acetate)/mometasone furoate 125/127.5 mcg powder for inhalation in hard capsule with inhaler Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bemrist breezhaler 125/127.5 indacaterol (as acetate)/mometasone furoate 125/127.5 mcg powder for inhalation in hard capsule with inhaler

grand medical pty ltd - mometasone furoate, quantity: 160 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - bemrist breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists

ATECTURA BREEZHALER 125/127.5 indacaterol (as acetate)/mometasone furoate 125/127.5 mcg powder for inhalation in hard capsule with inhaler Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

atectura breezhaler 125/127.5 indacaterol (as acetate)/mometasone furoate 125/127.5 mcg powder for inhalation in hard capsule with inhaler

novartis pharmaceuticals australia pty ltd - mometasone furoate, quantity: 160 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists

ULTIBRO BREEZHALER CAPSULE Kanada - angličtina - Health Canada

ultibro breezhaler capsule

novartis pharmaceuticals canada inc - glycopyrronium (glycopyrronium bromide); indacaterol (indacaterol maleate) - capsule - 50mcg; 110mcg - glycopyrronium (glycopyrronium bromide) 50mcg; indacaterol (indacaterol maleate) 110mcg - antimuscarinics antispasmodics

ATECTURA BREEZHALER INHALATION POWDER HARD CAPSULE 150 MCG 160 MCG Singapur - angličtina - HSA (Health Sciences Authority)

atectura breezhaler inhalation powder hard capsule 150 mcg 160 mcg

novartis (singapore) pte ltd - indacaterol acetate equivalent to indacaterol; mometasone furoate - powder, metered - indacaterol acetate equivalent to indacaterol 150 mcg; mometasone furoate 160 mcg

ATECTURA BREEZHALER INHALATION POWDER HARD CAPSULE 150 MCG 320 MCG Singapur - angličtina - HSA (Health Sciences Authority)

atectura breezhaler inhalation powder hard capsule 150 mcg 320 mcg

novartis (singapore) pte ltd - indacaterol acetate equivalent to indacaterol; mometasone furoate - powder, metered - indacaterol acetate equivalent to indacaterol 150 mcg; mometasone furoate 320 mcg